Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Pantoprazole and esomeprazole have equivalent effacacies in GERD treatment

Pantoprazole and esomeprazole have equivalent efficacies in GERD treatment, although pantaprazole may be safer in terms of drug-drug interactions, according to studies conducted in collaboration with Byk Gulden.

News image

fiogf49gjkf04

Proton pump inhibitors (PPIs) are the best treatment of GERD with or without endoscopic esophagitis.

However, optimal dosing of PPIs has been a matter of debate for several years.

A study published in Gastroenterology by Scholten and colleagues addressed this topic. It showed that 40 mg pantoprazole provided superior symptom relief to 20 mg omeprazole in 360 patients with severe heartburn.

In particular, the patients taking pantoprazole reported faster relief of their symptoms.

Patients taking omeprazole had to wait 4 days to experience the relief felt at only 2 days by patients receiving pantoprazole.

Other studies have suggested that treatment with 40 mg esomeprazole, the S-isomer of omeprazole, is superior to 20 mg omeprazole. Therefore, the latest studies compared pantoprazole with esomeprazole.

A pH-metry study by Simon et al., published in the American Journal of Gastroenterology, showed that 40 mg pantoprazole reduced the duration of reflux to the same extent as 40 mg esomeprazole.

This was a double-blind cross-over study of 48 patients with GERD symptoms and reflux occurring more than 6% of the time.

More recently, two studies have confirmed the milligram-for-milligram equivalence of pantoprazole and esomeprazole, in terms of both endoscopically confirmed healing and clinical symptoms.

Comparably high GERD healing rates were achieved with pantoprazole and esomeprazole.
Byk Gulden
Professor V. Stanghellini presented these on 2 November 2001, at the International Forum on Endoscopy, in his state-of-the-art lecture.

The first study was a double-blind trial, comparing the effects of equal doses of pantoprazole and esomeprazole on endoscopically confirmed healing in 227 GERD patients.

Patients were randomized to receive 40 mg of either pantoprazole or esomeprazole once daily.

Comparably high healing rates were achieved with pantoprazole (95%) and esomeprazole (90%), thereby demonstrating statistically significant equivalence of the two drugs.

Both drugs were well tolerated, and no drug-related adverse events were reported in either group.

The second study confirmed the efficacy of pantoprazole in treating the symptoms of GERD.

Over 200 patients took 40 mg of either pantoprazole or esomeprazole once daily, for 4 weeks.

They recorded the occurrence and severity of heartburn, belching, indigestion, pressure in the chest, and feelings of fullness and flatulence, using daily diaries.

Taking either pantoprazole or esomeprazole had a dramatic effect on their symptoms, confirming that they provide equivalent symptom relief.

There were no statistically significant differences in symptom load reduction, and both drugs were well tolerated.

Taken together, these studies clearly demonstrate that pantoprazole is equivalent to esomeprazole, on a mg-for-mg basis, comments Reiner Link, of Byk Gulden.

Treatment with pantoprazole leads to similar rates of healing and symptom relief. However, it has benefits over esomeprazole. In particular, it can be prescribed without concern over drug-drug interactions.

These have been a problem with other PPIs, which may react with common medications such as diazepam, phenytoin, and anticoagulants.

Studies with pantoprazole, however, have confirmed that it does not interact with these or any of the other drugs tested and so can be prescribed safely alongside co-medication.

Byk Gulden
06 December 2001

Go to top of page Email this page Email this page to a colleague

 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us